TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07729462: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, RANDOMIZED, 2-ARM STUDY TO INVESTIGATE THE PREVENTION OF CHRONIC MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN PARTICIPANTS 18 YEARS OF AGE OR OLDER

Sponsor: Pfizer · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$15,481,976

Rescue Site Savings

+$10,192,760

Unlock Full NCT07729462 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07729462 Rescue Dossier →